Proactive Investors - Run By Investors For Investors

Indivior falls again as US court ruling clears way for launch of Suboxone generic

Suboxone is Indivor’s big money-maker, but two generic versions could hit the market as early as next Tuesday after the latest ruling from a US appeals court
suboxone
Indivior is adamant that the generics infringe on its patents and is taking its case to the Supreme Court

Indivior PLC (LON:INDV) has been dealt another blow in its bid to protect its star drug after a US court ruling cleared the way for two rivals to launch their generic versions of the opioid addiction next week.

The drugmaker has been aggressively defending Suboxone, which makes up the bulk of its annual revenue, for several years now, claiming that cut-price treatments from Dr Reddy’s and Alvogen infringe on its patents.

READ: Federal court rejects Suboxone appeal

But last week, a US appeals court ratified an earlier decision by a district court in Delaware that gave the generics the all-clear.

Indivior is taking its case to the Supreme Court, the highest court in the US, and had hoped to delay the launch of the copycat versions until after then.

But that request has been rejected by the appeals court, which has told Indian giant Dr Reddy’s and Alvogen that they can start selling their drugs into the market next Tuesday (19 February).

Dr Reddy’s not averse to an ‘at-risk’ launch

Any launch would be on an ‘at-risk’ basis though – when litigation is still going – as Indivior is still trying to protect its intellectual property (IP) through a court in New Jersey as well as the Supreme Court.

That wasn’t a concern for Dr Reddy’s last summer though when it briefly launched its version ‘at-risk’ and took a decent chunk out of Suboxone’s market share despite only being available for a few hours.

Indivior shares were down 2.2% to 104.7p. Last summer they were changing hands for more than 500p.

View full INDV profile View Profile

Indivior Timeline

Article
September 23 2016

Related Articles

Sativa
April 02 2019
Geremy Thomas, founder and chief executive of Sativa, said the company has made significant progress since it started trading on NEX.
1542204301_heart.jpg
November 14 2018
The goal of the program is to extend the visualization extracted from 2D ultrasound images and visualize 4D images
Scientist
December 03 2018
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use